Vertex Pharmaceuticals (VRTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist

474.500
-4.600-0.96%

Close Feb 27 16:00 ET

472.000
-2.500-0.53%

Post 20:01 ET

121.85BMarket Cap-228.13P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wall Street Today: Market Decides Down is the Direction
Kevin Travers16:01 ET
Express News | Live On CNBC, Rob Sechan Announces Sold Vertex Pharmaceuticals
Benzinga12:33 ET
Live Stock News: Nvidia Does not run Things Around here Anymore
Kevin Travers11:06 ET
Jefferies Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550
Moomoo NewsFeb 27 09:33 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Vertex Pharmaceuticals (VRTX) and Viridian Therapeutics (VRDN)
TipRanksFeb 27 09:10 ET · Ratings
Wall Street Today: Market Quaking With Anticipation, and Nvidia Delivers Beat
Kevin TraversFeb 26 16:57 ET

Comments

Teddy123

Jan 31 01:16

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

$Vertex Pharmaceuticals (VRTX.US)$
Revolutionary Gene Therapy CASGEVY Now Available Through NHS England: Major Win for Sickle Cell Patients

Teddy123

Jan 30 23:42

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

$Vertex Pharmaceuticals (VRTX.US)$
FDA Approves First Non-Opioid Pain Drug in 20 Years: Vertex's Game-Changing Alternative to Opioids

Stock_Drift

Jan 30 19:13

$Vertex Pharmaceuticals (VRTX.US)$

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Lnova

Jan 28 03:25

$Vertex Pharmaceuticals (VRTX.US)$ am watching this one to see the outcome biopharmcatalys...
has options
“Suzetrigine: The FDA has assigned a PDUFA target action date of January 30, 2025, for suzetrigine for the treatment of moderate-to-severe acute pain. Suzetrigine was granted Priority Review by the FDA.
The Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act became effective on January 1st, 2025. The NOPAIN Act mandates that Medicare provide a separate add-on payment in the hospital outp...

101721316

Dec 29, 2024 04:21

$Vertex Pharmaceuticals (VRTX.US)$ long term play

VRTX Vertex Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks